One of the companies will be geared toward the development and marketing of biopharmaceuticals with an emphasis on improving diagnosis, treatment and standard of care for a variety of bleeding disorders and chronic conditions. The company will be named at a later time and will be led by Ludwig Hanston, PhD.
The other company will focus on life-saving medical products, such as intravenous solutions, nutritional therapies, drug delivery systems, inhalation anesthetics and biosurgery products. The medical product company will retain the Baxter International name. Robert Parkinson, Jr., has been selected as chairman and CEO of the company.
The final transaction to create the two companies, in the form of tax-free distributions to Baxter shareholders of new publicly traded stock in the biopharmaceutical company, is expected to be finalized by mid-2015.
More Articles on Hospital Supply Chain:
FDA Approves Alprolix for Hemophilia B Treatment
FDA Importing Saline From Norway to Ease Shortage
14 Device Recalls in 2014
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
